1021-91-6

Basic information

• Product Name: 5H-dibenzo[a,d]cyclohepten-5-one oxime
• Synonyms: 5H-dibenzo[a,d]cyclohepten-5-one oxime;5H-Dibenzo[a,d][7]annulen-5-one oxime
• CAS NO: 1021-91-6
• Molecular Formula: C₁₅H₁₁NO
• Molecular Weight: 221.25394
• EINECS: 213-820-0
• Mol File: 1021-91-6.mol
• Article Data: 17

Chemical Properties

• Melting Point: 187-188 °C
• Boiling Point: 398.4°Cat760mmHg
• Flash Point: 255.5°C
• Appearance: /
• Density: 1.16g/cm³
• Vapor Pressure: 4.61E-07mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: 2-8°C
• PKA: 10.65±0.20(Predicted)
• CAS DataBase Reference: 5H-dibenzo[a,d]cyclohepten-5-one oxime(CAS DataBase Reference)
• NIST Chemistry Reference: 5H-dibenzo[a,d]cyclohepten-5-one oxime(1021-91-6)
• EPA Substance Registry System: 5H-dibenzo[a,d]cyclohepten-5-one oxime(1021-91-6)

Safety Data

• Hazardous Substances Data: 1021-91-6(Hazardous Substances Data)

Usage

General Description

5H-dibenzo[a,d]cyclohepten-5-one oxime, also known as DXO, is a chemical compound that has been studied for its potential pharmacological properties. It has been shown to act as a potent, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, which is involved in synaptic transmission and plasticity in the central nervous system. This suggests that DXO may have potential applications in the treatment of neurological disorders such as Alzheimer's disease, Parkinson's disease, and schizophrenia. Additionally, DXO has been found to have anti-inflammatory and analgesic properties, further expanding its potential therapeutic uses. Research on DXO and its derivatives continues to explore their diverse pharmacological effects and potential clinical applications.

InChI:InChI=1/C15H11NO/c17-16-15-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)15/h1-10,17H

Upstream product

• 2222-33-5 dibenzosuberenon 

Downstream Products

• 24701-51-7 demexiptiline 
• 833-48-7 dibenzosuberane 
• 23112-88-1 dibenzo[b,f]azocin-6(5H)-one 
• 1255942-06-3 N-(3-aminopropionyl)-5,6-dihydro-11,12-didehydrodibenzo[b,f]azocine 
• 1255942-07-4 DBCO-4PEG-biotin 
• 1255942-12-1 N-boc protected ADIBO-PEG₄-amine 
• 1255942-08-5 DBCO-PEG₄-amine 
• 1337920-23-6 N-(3-trifluoroacetamidopropanoyl)-5,6-Dihydro-11,12-Didehydrodibenzo[b,f]azocine 
• 23194-93-6 (Z)-5,6-dihydrodibenzo[b,f]azocine 
• 1341223-26-4 N-(6-(1-benzyl-1H-dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-8(9H)-yl)-6-oxohexyl)-4-[18F]fluorobenzamide 
• 1341223-27-5 32-(8-(6-(4-[18F]fluorobenzamido)hexanoyl)-8,9-dihydro-1H-dibenzo[b,f][1,2,3]triazolo-[4,5-d]azocin-1-yl)-5-oxo-3,9,12,15,18,21,24,27,30-nonaoxa-6-azadotriacontan-1-oic acid 
• 23112-88-1 dibenzo[b,f]azocin-6(5H)-one 
• 23194-93-6 2-azatricyclo[10.4.0.0^4,9]hexadeca-1⁽¹⁶⁾,4⁽⁹⁾,5,7,10,12,14-heptene 
• 1341223-25-3 C₂₈H₂₅⁽¹⁸⁾FN₂O₂ 

Relevant articles and documents

Novel dibenzosuberene substituted aroyl selenoureas: Synthesis, crystal structure, DFT, molecular docking and biological studies

A series of aroyl selenourea dibenzosuberene (1–3) derivatives were synthesized and characterized by different analytical methods and single crystal X-ray crystallography. Quantum chemical computations were made using DFT to determine the structural and molecular properties of the compounds. The in?vitro antibacterial action of the compounds was evaluated against chosen gram-negative (Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli), and gram-positive (Bacillus subtilis, Staphylococcus aureus, and Staphylococcus epidermidis) bacteria for their antifungal activity against Curvularia lunata, Penicillium notatum, and Aspergillus niger. Using molecular docking studies, the binding modes were understood along with the mechanism in opposing the target protein MurB.

Highly Efficient Multigram Synthesis of Dibenzoazacyclooctyne (DBCO) without Chromatography

The synthesis of 4-[11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl]-4-oxobutanoic acid, also known as dibenzoazacyclooctyne (DBCO) or aza-dibenzocyclooctyne (ADIBO), was optimized for large-scale preparations of at least 10 g with an overall yield of 42%.

A two-step strategy to radiolabel choline phospholipids with99mTc in S180 cell membranes via strain-promoted cyclooctyne–azide cycloaddition reaction

As tumor markers, the radiolabeling of choline (Cho)-containing phospholipids in cellular membranes with99mTc is a challenge. The conventional strategy to combine the metallic radionuclide with Cho by large ligand damages the bioactivity of Cho, resulting in low tumor-to-nontumor ratios. Pretargeting strategy based on strain-promoted cyclooctyne–azide cycloaddition (SPAAC) reaction was applied to solve this general problem. Functional click synthons were synthesized as pretargeting components: azidoethyl-choline (AECho) serves as tumor marker and azadibenzocyclooctyne (ADIBO) conjugated to bis(2-pieolyl) amine (BPA) ligand (ADIBO-BPA) as99mTc(CO)3-labeling and azido-binding group. Both in vitro cell experiment and in vivo biodistribution experiment indicate that it is versatile to radiolabel Cho in cellular membranes via this two-step pretargeting strategy. We believe that this pretargeting strategy can indeed enhance the target-specificity and also reduce background signals to optimize imaging quality.

Manipulating the Click Reactivity of Dibenzoazacyclooctynes: From Azide Click Component to Caged Acylation Reagent by Silver Catalysis

Strain-promoted azide–alkyne cycloaddition using dibenzoazacyclooctyne (DBCO) is widely applied in copper-free bioorthogonal reactions. Reported here is the efficient acid-promoted rearrangement and silver-catalyzed amidation of DBCO, which alters its click reactivity robustly. In the switched click reaction, DBCO, as a caged acylation reagent, enables rapid peptide/protein modification after decaging facilitated by silver catalysts, rendering site-specific conjugation of an IgG antibody by a Fc-targeting peptide.